The study was approved by the institutional review board and was conducted in compliance with the Declaration of Helsinki.

NE: Research funding: Beigene, Lilly, and Incyte; Speakers Bureau for Beigene and Genentech; Ad boards for ADC Therapeutics, Lilly, and Ipsen; Honorarium from Novartis. TJV: Advisory Board: Genmab/AbbVie, ADC Therapeutics. Consultancy: Novartis, Recordati, Genmab. Research Funding: Kite, Viracta, Incyte/Morphosys, Genmab/AbbVie, Recordati. DAB: Advisory Board: Novartis, Nurix Therapeutics, ADC Therapeutics. Research Funding: Novartis, Kite/Gilead, Accutar, Nurix Therapeutics, Incyte, GenMab, BeiGene. Astra Zeneca.BC Advisory Board: Ipsen, AstraZeneca; Research Support: Genentech, Acerta, Millenium, Kite, Bristol Myers Squibb KM: Consulting: AbbVie, ADC Therapeutics, AstraZeneca/Acerta, Beigene, BMS, Caribou, Genentech, Genmab, Gilead/KITE, Incyte, Janssen, Lilly, Morphosys, Pharmacyclics.